UTMB to lead program to advance treatments against potentially bioterrorist pathogens

The University of Texas Medical Branch at Galveston, Profectus Biosciences, Vanderbilt University Medical Center, Mapp Biopharmaceutical and Genevant Sciences Corp. have been awarded up to $35 million to advance the development of rapid-acting vaccines and broad-spectrum treatments of the highly-lethal hemorrhagic fever viruses Ebola and Marburg.

HHS’ BARDA Funds Its First Marburg Virus Vaccine Development

To increase national health security against biothreats and protect public health, the US Department of Health and Human Services (HHS) will partner with Public Health Vaccines LLC of Cambridge, Massachusetts, to develop a potential vaccine against Marburg virus. No licensed vaccine for this virus exists today.